



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



MRTX-0902

Item No. 38578

CAS Registry No.: 2654743-22-1
Formal Name: 2-methyl-3-[(1R)-1-[[4-methyl-7-(4-morpholinyl)pyrido[3,4-d]pyridazin-1-yl]amino]ethyl]-benzonitrile
MF: C₂₂H₂₄N₆O
FW: 388.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MRTX-0902 is supplied as a solid. A stock solution may be made by dissolving the MRTX-0902 in the solvent of choice, which should be purged with an inert gas. MRTX-0902 is soluble in acetonitrile.

Description

MRTX-0902 is an inhibitor of the protein-protein interaction between son of sevenless homolog 1 (SOS1) and K-Ras containing a glycine-to-cysteine mutation at position 12 (K-Ras^{G12C}; K_i = 1.9 nM).¹ It is selective for the SOS1-K-Ras^{G12C} protein-protein interaction over the SOS1 and wild-type K-Ras protein-protein interaction (IC₅₀ = >10,000 nM). MRTX-0902 decreases phosphorylated ERK levels in MKN1 gastric adenocarcinoma cells (IC₅₀ = 29 nM). *In vivo*, MRTX-0902 (25 or 50 mg/kg twice per day), in combination with the covalent inhibitor of K-Ras^{G12C} MTX-849 (Item No. 31440), reduces tumor volume and phosphorylated ERK levels in a PaCa-2 pancreatic cancer mouse xenograft model.

Reference

1. Ketcham, J.M., Haling, J., Khare, S., *et al.* Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein-protein interaction. *J. Med. Chem.* **65**(14), 9678-9690 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM